Literature DB >> 10627219

Suppression of noxious stimulus-evoked expression of Fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist.

K Tsou1, K A Lowitz, A G Hohmann, W J Martin, C B Hathaway, D A Bereiter, J M Walker.   

Abstract

In rats, cannabinoids inhibit behavioral responses to noxious stimulation with a potency and efficacy similar to that of morphine. However, because cannabinoids depress motor function, it has not been possible to state beyond any doubt that these effects were related to a dampening of noxious sensory input. Therefore, c-fos immunocytochemistry was used to explore the possibility that cannabinoids reduce behavioral responses to noxious stimuli by decreasing spinal processing of nociceptive inputs. Rats received systemic injections of the potent and selective cannabinoid agonist WIN 55,212-2, the receptor-inactive enantiomer WIN 55,212-3 or vehicle prior to observations in a model of tonic pain, the formalin test. As demonstrated previously, plantar injections of formalin led to lifting and licking of the injected paw, with two peaks of activity occurring at 5 and 30 min after injection. The cannabinoid agonist suppressed these pain responses and produced a reduction in mobility. Immunocytochemical processing of sections with an antibody to the Fos protein revealed that the cannabinoid markedly suppressed pain-evoked c-fos expression in the superficial and neck regions of the spinal dorsal horn, but not in the nucleus proprius. Decreased expression of c-fos also occurred in the ventral horn. The specificity of this effect and its probable mediation by cannabinoid receptors are suggested by three findings: (i) the suppression by the drug of both behavioral and immunocytochemical responses to pain was dose-dependent; (ii) neither the behavioral nor the immunocytochemical response to the noxious stimulus was significantly affected by the receptor-inactive enantiomer of the agonist; (iii) animals rendered tolerant to cannabinoids by repeated injections of the agonist showed reduced responses to the drug. These findings suggest that cannabinoids inhibit the spinal processing of nociceptive stimuli and support the notion that endogenous cannabinoids may act naturally to modify pain trnasmission within the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 10627219     DOI: 10.1016/s0306-4522(96)83015-6

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  21 in total

Review 1.  The endocannabinoid system and pain.

Authors:  Josée Guindon; Andrea G Hohmann
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

2.  Bilateral changes of cannabinoid receptor type 2 protein and mRNA in the dorsal root ganglia of a rat neuropathic pain model.

Authors:  Ivana Hradilová Svízenská; Václav Brázda; Ilona Klusáková; Petr Dubový
Journal:  J Histochem Cytochem       Date:  2013-05-08       Impact factor: 2.479

Review 3.  Physical activity and the endocannabinoid system: an overview.

Authors:  Mirko Tantimonaco; Roberta Ceci; Stefania Sabatini; Maria Valeria Catani; Antonello Rossi; Valeria Gasperi; Mauro Maccarrone
Journal:  Cell Mol Life Sci       Date:  2014-02-14       Impact factor: 9.261

4.  Antiproliferative effects of cannabinoid agonists on deep infiltrating endometriosis.

Authors:  Mahaut Leconte; Carole Nicco; Charlotte Ngô; Sylviane Arkwright; Christiane Chéreau; Jean Guibourdenche; Bernard Weill; Charles Chapron; Bertrand Dousset; Frédéric Batteux
Journal:  Am J Pathol       Date:  2010-11-05       Impact factor: 4.307

5.  Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation.

Authors:  M Tognetto; S Amadesi; S Harrison; C Creminon; M Trevisani; M Carreras; M Matera; P Geppetti; A Bianchi
Journal:  J Neurosci       Date:  2001-02-15       Impact factor: 6.167

6.  Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects.

Authors:  W J Martin; A G Hohmann; J M Walker
Journal:  J Neurosci       Date:  1996-10-15       Impact factor: 6.167

Review 7.  Modulation of pain transmission by G-protein-coupled receptors.

Authors:  Hui-Lin Pan; Zi-Zhen Wu; Hong-Yi Zhou; Shao-Rui Chen; Hong-Mei Zhang; De-Pei Li
Journal:  Pharmacol Ther       Date:  2007-09-22       Impact factor: 12.310

8.  CB1 cannabinoid receptor activation inhibits a neural correlate of song recognition in an auditory/perceptual region of the zebra finch telencephalon.

Authors:  Osceola Whitney; Ken Soderstrom; Frank Johnson
Journal:  J Neurobiol       Date:  2003-09-05

9.  Small molecule inhibitors of PSD95-nNOS protein-protein interactions suppress formalin-evoked Fos protein expression and nociceptive behavior in rats.

Authors:  Lawrence M Carey; Wan-Hung Lee; Tannia Gutierrez; Pushkar M Kulkarni; Ganesh A Thakur; Yvonne Y Lai; Andrea G Hohmann
Journal:  Neuroscience       Date:  2017-03-08       Impact factor: 3.590

10.  Peripheral and central sites of action for the non-selective cannabinoid agonist WIN 55,212-2 in a rat model of post-operative pain.

Authors:  C Z Zhu; J P Mikusa; Y Fan; P R Hollingsworth; M Pai; P Chandran; A V Daza; B B Yao; M J Dart; M D Meyer; M W Decker; G C Hsieh; P Honore
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.